Zevra Therapeutics, Inc. (ZVRA) Stock Analysis
A live, multi-source view of Zevra Therapeutics, Inc. (ZVRA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA.
Sector: Healthcare · Industry: Biotechnology · United States · 61 employees · zevra.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Zevra Therapeutics, Inc. (ZVRA) had a market capitalization of $736.4M, a trailing P/E of 13.3 (forward 11.5) and a beta of 0.95; the shares traded in a 52-week range of $7.16 – $15.04 (48.9% over the year).
- Market cap
- $736.4M
- Enterprise value
- $516.3M
- Trailing P/E
- 13.3
- Forward P/E
- 11.5
- PEG ratio
- 10.67
- Price / book
- 3.38
- EPS (trailing)
- $0.93
- EPS (forward)
- $1.08
- Payout ratio
- 0.0%
- 52-week range
- $7.16 – $15.04
- 52-week change
- 48.9%
- Beta
- 0.95
- Average volume
- 1.4M
- Shares outstanding
- 59.4M
- Short % of float
- 11.02%
- Profit margin
- 42.8%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Zevra Therapeutics, Inc. (ZVRA) last closed at $12.06 (the last completed close before that scan).
Technicals at the scan: RSI 52 (neutral territory), price +1.3% versus its 20-day average, 20-day versus 50-day average spread -0.3%, MACD histogram 0.05.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 81/100.
Next scheduled company event: in 54 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of ZVRA; corporate insiders filed 0 buys and 2 sells (2 distinct filers, latest disclosure 2026-08-17). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Rahsaan Thompson (0B/1S), Corey Michael Watton (0B/1S). Who is trading what
RapidTradeView pick record
ZVRA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Zevra Therapeutics, Inc. (ZVRA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell ZVRA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.